Trulieve to Become First U.S. Marijuana Company Listed on Major U.S. Stock Exchange
- Trulieve Cannabis Corp. became the first U.S. marijuana company approved to list its shares on the New York Stock Exchange, with trading under the ticker symbol TRLV starting June 10.
- The company will continue trading on the Canadian Securities Exchange and OTCQX until June 9, with no action required from current shareholders for the NYSE listing.
- Trulieve recently restructured by separating its mixed-use marijuana business from its medical marijuana operations, focusing its consolidated business exclusively on state-licensed medical marijuana facilities.
- Following the reclassification of medical marijuana to Schedule III in April 2026, Trulieve is positioned for growth with extensive operations and planned expansions in Georgia and Texas.
Trulieve Cannabis Corp. announced today that its subordinate voting shares have been approved for listing on the New York Stock Exchange, making it the first U.S. marijuana company to list on a major U.S. exchange.
The company said its shares are expected to begin trading on the NYSE under the ticker symbol TRLV at the opening of trading on Wednesday, June 10.
Trulieve, which currently trades on the Canadian Securities Exchange under the symbol TRUL and on the OTCQX under the symbol TCNNF, said both listings are expected to continue until the close of market on June 9. Current shareholders do not need to take any action before the NYSE listing.
“As the first U.S. cannabis company to list on a major U.S. exchange, we are excited for the opportunity to expand our shareholder base, increase liquidity, and raise awareness for the benefits of medical marijuana,” said Trulieve Founder and CEO Kim Rivers. “Common sense action by President Trump to reclassify medical marijuana to Schedule III paved the way for this historic milestone.”
The announcement follows the company’s recently completed corporate restructuring, which separated its mixed-use marijuana business from its medical marijuana business. Trulieve said the move resulted in the deconsolidation of operations in markets serving both medical and adult-use customers.
Trulieve’s remaining consolidated operations consist only of state-licensed medical marijuana facilities, including 206 medical marijuana dispensaries supported by 3.5 million square feet of production capacity registered with the Drug Enforcement Administration.
The company said medical marijuana was reclassified to Schedule III in April 2026 following an executive order issued by President Donald Trump in December 2025. Trulieve said the final order rescheduled state-licensed medical marijuana products and created a pathway for DEA registration for state-licensed medical marijuana businesses.
Rivers said the company is “well positioned” for future growth, citing its medical marijuana operations and planned expansion in Georgia and Texas.
Trulieve is a vertically integrated marijuana company with medical marijuana operations in Florida, Georgia, Pennsylvania and West Virginia.